ArticleAdvances in urology2012
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder.
Article in Advances in urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- A Machine Learning Computational Framework Develops a Multiple Programmed Cell Death Index for Improving Clinical Outcomes in Bladder Cancer.Biochemical genetics · 2024Article
- A Novel Multiepitope Vaccine Against Bladder Cancer Based on CTL and HTL Epitopes for Induction of Strong Immune Using Immunoinformatics Approaches.International journal of peptide research and therapeutics · 2022Article
- Review
- Article
- Diagnostic biomarkers in non-muscle invasive bladder cancer.World journal of urology · 2019Review
- Comparing urine levels of BLCA-4 nuclear matrix protein in patients with bladder cancer and non-bladder cancer.International journal of physiology, pathophysiology and pharmacology · 2019Article
- A risk score staging system based on the expression of seven genes predicts the outcome of bladder cancer.Oncology letters · 2018Article
- Clinical Significance of Serological and Urological Levels of Bladder Cancer-Specific Antigen-1 (BLCA-1) in Bladder Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- The contemporary role and impact of urine-based biomarkers in bladder cancer.Translational andrology and urology · 2017Review
- Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer.Current urology reports · 2017Review
- The Diagnostic Value of Nuclear Matrix Proteins in Bladder Cancer in the Aspect of Environmental Risk from Carcinogens.BioMed research international · 2017Article
- Tumor abnormal protein (TAP) examination contributes to primary diagnosis of bladder cancer.International journal of clinical and experimental medicine · 2015Article
- Interaction network analysis of differentially expressed genes and screening of cancer marker in the urine of patients with invasive bladder cancer.International journal of clinical and experimental medicine · 2015Article
- Urothelial Bladder Cancer Urinary Biomarkers.EJIFCC · 2014Article
- Gene microarray analysis of the lncRNA expression profile in human urothelial carcinoma of the bladder.International journal of clinical and experimental medicine · 2014Article
- Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transitional cell carcinoma (TCC) of the bladder is one of the most common malignancies of genitourinary tract. Patients with bladder cancer need a life-long surveillance, directly due to the relatively high recurrence rate of this tumor. The use of cystoscopy represents the gold standard for the followup of previously treated patients. Nevertheless, several factors, including cost and invasiveness, render cystoscopy not ideal for routine controls. Advances in the identification of specific alterations in the nuclear structure of bladder cancer cells have opened novel diagnostic landscapes. The members of nuclear matrix protein family BLCA-1 and BLCA-4, are currently under evaluation as bladder cancer urinary markers. They are involved in tumour cell proliferation, survival, and angiogenesis. In this paper, we illustrate the role of BLCA-1 and BLCA-4 in bladder carcinogenesis and their potential exploitation as biomarkers in this cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.